Abstract

Review Article

Evaluation of the Social Return on Investment (SROI) in Patients with Hepatitis C. The Case of the Mobile Outreach Program (MOP)

Paulo Lopes, Georg Dutschke*, Cláudia Pereira, Elsa Belo, Diogo Morais, Paulo Caldeira, Filipa Barata, Emília Leitão, R Tato Marinho, Paula Peixe, José Vera and Rodrigo Coutinho

Published: 09 September, 2024 | Volume 8 - Issue 1 | Pages: 009-015

The World Drug Report highlights that the prevalence of hepatitis C virus (HCV) is one of the leading causes of cirrhosis and hepatocellular carcinoma globally. This report estimates that HCV is responsible for the annual death of around 700,000 people due to liver disease and is associated with high levels of morbidity and mortality with high health and socio-economic costs. This exploratory study aims to evaluate the socio-economic return provided by HCV treatment of individuals integrated into the MOP developed by the NGO Ares do Pinhal in Portugal. Using the SROI (Social Return on Investment) methodology is estimated that for every euro invested in this program, the return for society is 3,75€. This is a significantly positive SROI value, highlighting the importance of this investment in the creation of monetized value for society, as well as to provide greater well-being to those who need it and to society as a whole.

Read Full Article HTML DOI: 10.29328/journal.jatr.1001029 Cite this Article Read Full Article PDF

Keywords:

Addictive behaviors and dependencies; Hepatitis C; Mobile Outreach Program (MOP); Social Return on Investment (SROI)

References

  1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European drug report 2016: trends and developments. Luxembourg: Publications Office of the European Union; 2016. Available from: https://www.euda.europa.eu/publications/edr/trends-developments/2016_en
  2. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European drug report 2019: trends and developments. Available from: https://www.emcdda.europa.eu/system/files/publications/11364/20191724_TDAT19001ENN_PDF.pdf
  3. Peterson C, Li M, Xu L, Mikosz CA, Luo F. Assessment of annual cost of substance use disorder in US hospitals. JAMA Netw Open. 2021;4(3): e210242. Available from: https://doi.org/10.1001%2Fjamanetworkopen.2021.0242
  4. Bouzanis K, Joshi S, Lokker C, Pavalagantharajah S, Qiu Y, Sidhu H, Alvarez E. Health programs and services addressing the prevention and management of infectious diseases in people who inject drugs in Canada: a systematic integrative review. BMJ Open. 2021;11(9):e047511. Available from: https://doi.org/10.1136/bmjopen-2020-047511
  5. World Health Organization (WHO). Guidelines for the screening, care, and treatment of persons with chronic hepatitis C infection. Update version; 2016. Available from:: https://www.ncbi.nlm.nih.gov/books/NBK362924/.
  6. Petruzziello A, Margliano S, Loquercio G, Cozzolino A, Cacciapioti C. Global epidemiology of hepatitis C virus infection: an update of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22:7824-40. Available from: https://doi.org/10.3748/wjg.v22.i34.7824
  7. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29:74-81. Available from: https://doi.org/10.1111/j.1478-3231.2008.01934.x
  8. United Nations Office on Drugs and Crime (UNODC). World drug report 2016. United Nations publication, Sales No. E.16.XI.7; 2017.
  9. Silva MJ, Pereira C, Loureiro R, Balsa C, Lopes P, Água-Doce I, Belo E, Martins HC, Coutinho R, Pádua E. Hepatitis C in a mobile low-threshold methadone program. Eur J Gastroenterol Hepatol. 2017;29:657-62. Available from: https://journals.lww.com/eurojgh/abstract/2017/06000/hepatitis_c_in_a_mobile_low_threshold_methadone.7.aspx
  10. European Centre for Disease Prevention and Control (ECDC). Hepatitis C surveillance in Europe 2013. Available at: Available from: https://www.ecdc.europa.eu/en/publications-data/hepatitis-c-surveillance-europe-2013
  11. World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016–2021. Geneva: World Health Organization; 2016. Available from: https://www.afro.who.int/sites/default/files/2017-06/WHO-HIV-2016.06-eng.pdf
  12. Anjo J, Café A, Carvalho A, Doroana M, Fraga J, Gíria J,, et al. O impacto da hepatite C em Portugal. J Port Gastroenterol. 2014;21:44-54. Available from: https://doi.org/10.1016/j.jpg.2014.03.001
  13. Marinho R, Vítor S, Velosa J. Benefits of curing hepatitis C infection. J Gastrointest Liver Dis. 2014;23:85-90. Available from: https://pubmed.ncbi.nlm.nih.gov/24689102/
  14. Smith D, Combellick J, Jordan A, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. Int J Drug Policy. 2015;26:911-21. Available from: https://doi.org/10.1016/j.drugpo.2015.07.004
  15. Marinho R, Barreira D. Hepatitis C, stigma and cure. World J Gastroenterol. 2013;19:6703-9. Available from: https://doi.org/10.3748/wjg.v19.i40.6703
  16. Ormeci N, Yüksel O, Keskin O,, et al. Treatment of HCV infection with direct-acting antiviral agents. Real-life experiences from the Euro-Asian region. Turk J Gastroenterol. 2020;31:148. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062133/
  17. Falcão F, Lopes C, Viegas E, Perez R, Aldir I, Farinha H,, et al. Experiência de um centro Português: eficácia dos Antivirais de Ação Direta no tratamento da Hepatite C. Acta Med Port. 2019;32:189-94. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10655
  18. Brest P, Harvey H. Money well spent: A strategic plan for smart philanthropy. Stanford (CA): Stanford Business Books; 2008.
  19. García A, García MY. Analysis of social return on investment in two support systems for people with severe disabilities: personal assistance and residential service. A case study. Rev Esp Disability. 2014;2:51-69. Available from: http://dx.doi.org/10.5569/2340-5104.02.01.03
  20. Scholten P, Nicholls J, Olsen S, Galimidi B. Social return on investment: A guide to SROI analysis. Amstelveen: Lenthe Publishers; 2006.
  21. Nicholls J, Lawlor E, Neitzert E, Tim G. A guide to social return on investment. Available from: http://socialvalueuk.org.
  22. Roux HN. El SROI, un método para ayudar a medir las inversiones sociales. Fund Dialnet. 2012;241:48-55.
  23. Hubberstey C, Rutman D. HerWay Home Program for Pregnant and Parenting Women Using Substances: A brief social return on investment analysis. Can J Addict. 2020;11:6-14. Available from: http://dx.doi.org/10.1097/CXA.0000000000000086
  24. Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019;393(10178):1319-29. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32277-3/fulltext
  25. Blake A, Smith JE. Modeling hepatitis C elimination among people who inject drugs in New Hampshire. JAMA Netw Open. 2021;4(8):e2119092. Available from: https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2782630
  26. Dieterich DT. A simplified algorithm for the management of hepatitis C infection. Gastroenterol Hepatol (N Y). 2019;15(5 Suppl 3):1. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799873/
  27. Lopes P, Trigo H, Coutinho R, Leitão E, Miguel N, Oliveira J. Low Threshold Methadone Program: 13 years of experience in Portugal. In: Smith C, Marshall Z, editors. Critical Approaches to Harm Reduction: Conflict, Institutionalization, (De-)Politicization, and Direct Action. New York: Nova Publishers; 2016;23-40. Available from: https://research.ulusofona.pt/pt/publications/low-threshold-methadone-program-13-years-of-experience-in-portuga-2
  28. Yin RK. Case study research design and methods: Applied social research and methods series. 2nd ed. Thousand Oaks (CA): Sage Publications; 1994.
  29. Wei A, Lim SG, Xie Q, Kính NV, Piratvisuth T, Huang Y,, et al. Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. 2019;4(2):127-134. Available from: http://dx.doi.org/10.1016/S2468-1253(18)30343-1

Figures:

Similar Articles

  • Evaluation of the Social Return on Investment (SROI) in Patients with Hepatitis C. The Case of the Mobile Outreach Program (MOP)
    Paulo Lopes, Georg Dutschke*, Cláudia Pereira, Elsa Belo, Diogo Morais, Paulo Caldeira, Filipa Barata, Emília Leitão, R Tato Marinho, Paula Peixe, José Vera and Rodrigo Coutinho Paulo Lopes, Georg Dutschke*, Cláudia Pereira, Elsa Belo, Diogo Morais, Paulo Caldeira, Filipa Barata, Emília Leitão, R Tato Marinho, Paula Peixe, José Vera, Rodrigo Coutinho. Evaluation of the Social Return on Investment (SROI) in Patients with Hepatitis C. The Case of the Mobile Outreach Program (MOP). . 2024 doi: 10.29328/journal.jatr.1001029; 8: 009-015

Recently Viewed

Read More

Most Viewed

Read More

Help ?